John Celebi
Chief Executive Officer at SENSEI BIOTHERAPEUTICS, INC.
Net worth: 105 420 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bob Holmen | M | 60 |
Panacea Pharmaceuticals, Inc.
 Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | 7 years |
| Thomas Ricks | M | 70 |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | 9 years |
| Jessie English | M | 60 | 5 years | |
| Erin Colgan | F | 43 | 4 years | |
| William Ringo | M | 78 | 2 years | |
| James Peyer | M | - |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | 4 years |
| Christopher Gerry | M | - | 2 years | |
| Eliane Piaggio | F | - |
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | - |
| Edward van der Horst | M | 51 | 5 years | |
| Kristian Humer | M | 49 | 3 years | |
| James Peyer | M | 37 | 4 years | |
| Deneen Vojta | M | 59 | 4 years | |
| Felice Verduyn-van Weegen | F | - |
Egle Therapeutics SAS
Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | - |
| Pierre Legault | M | 63 |
Egle Therapeutics SAS
Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | 2 years |
| Vincent Brichard | M | - |
Egle Therapeutics SAS
Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | - |
| Patrick Gallagher | M | 44 | 2 years | |
| Mahmood Moshiri | M | 67 |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | 34 years |
| Alice Drumheller | F | - | 6 years | |
| Zhi-Gang Jiang | M | - |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | 22 years |
| Sacha Mann | F | - |
Egle Therapeutics SAS
Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | - |
| Jean-Francois Morineau | M | - |
Egle Therapeutics SAS
Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | - |
| Steven A. Fuller | M | - |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | - |
| Bao Le | F | - | 3 years | |
| Michael Biega | M | - | 2 years | |
| Shinji Takeichi | M | - |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | 20 years |
| Stephanie Krebs | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Weiskopf | M | 73 | 12 years | |
| Samuel Broder | M | 79 |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | 5 years |
| Paolo Pucci | M | 63 | - | |
| Stephen Hill | M | 65 | 9 years | |
| Mary Haak-Frendscho | M | 67 |
Igenica Biotherapeutics, Inc.
 Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | 2 years |
| Richard H. Woodrich | M | 78 | 1 years | |
| Gwen A. Fyfe | M | 72 |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | - |
| David Hastings | M | 62 | 3 years | |
| Thomas C. K. Chan | M | 68 | 7 years | |
| Thi-Sau Migone | M | - |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | - |
| Paul Sauer | M | 63 |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | 3 years |
| Robert Pierce | M | 59 | 2 years | |
| William Ho | M | 58 |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | 4 years |
| Nigel John Rulewski | M | 71 | - | |
| Randall L. Halcomb | M | - |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | - |
| Hans van Houte | M | 58 |
Igenica Biotherapeutics, Inc.
Igenica Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Igenica Biotherapeutics, Inc. develops therapeutics for the treatment of cancer. It develops antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The firm offers recombinant monoclonal antibodies for oncology and cancer treatment. The company was founded by Robert Schreiber and Guoqing Chen in 2008 and is headquartered in Burlingame, CA. | - |
| Anupama Hoey | F | 53 | 1 years | |
| Nancy Simonian | M | 63 | 5 years | |
| Brian Schwartz | M | 52 | 12 years | |
| Nancy Lurker | F | 66 |
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | 2 years |
| Peter S. Lawrence | M | 60 | - | |
| Louise A. Mawhinney | F | 68 | 3 years | |
| Chiang J. Li | M | 59 | 4 years | |
| Michael Loberg | M | 76 | 13 years | |
| J. David Jacobs | M | - | 3 years | |
| Michael Astrue | M | 67 | - | |
| John M. Sorvillo | M | 69 | 10 years | |
| Tuan Ha-Ngoc | M | 72 | 4 years | |
| Werner Cautreels | M | 71 | 7 years | |
| Laura Avakian | F | 78 | - | |
| Andrew C. G. Uprichard | M | 66 | 1 years | |
| Marie-Louise Fjaellskog | M | 59 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 52 | 89.66% |
| France | 6 | 10.34% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- John Celebi
- Personal Network
